Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8292446 | 0.87 | TRPV1 (0.81) | TRPV1 | |
| SCHEMBL3880343 | 0.86 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL3881001 | 0.86 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL3872137 | 0.86 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL3873424 | 0.86 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL18573111 | 0.85 | TRPV1 (0.80) | TRPV1 | |
| SCHEMBL5934511 | 0.85 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL5934750 | 0.85 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL5934651 | 0.84 | TRPV1 (1.00) | TRPV1 | |
| SCHEMBL5934238 | 0.84 | TRPV1 (0.73) | TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664041-B1 | PHENYL-CARBOXAMIDE COMPOUNDS USEFUL FOR TREATING PAIN | EURO CELTIQUE SA (LU) | 2008-07-02 | — | — | EP | claimed |
| EP-1575918-A2 | SUBSTITUTED BIARYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2004056774-A2 | SUBSTITUTED BIPHENYL-4-CARBOXYLIC ACID ARYLAMIDE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-08 | — | — | WO | claimed |
| US-8222275-B2 | Biarylcarboxyarylamides as vanilloid-1 receptor modulators | PHARMESTE S.R.L. (IT) | 2012-07-17 | — | — | US | disclosed |
| US-8222275-B2 | Biarylcarboxyarylamides as vanilloid-1 receptor modulators | PHARMESTE S.R.L. (IT) | 2012-07-17 | — | — | US | disclosed |
| US-8129388-B2 | Therapeutic agents useful for treating pain | Purde Pharma L.P. (US) | 2012-03-06 | — | — | US | disclosed |
| US-8129388-B2 | Therapeutic agents useful for treating pain | Purde Pharma L.P. (US) | 2012-03-06 | — | — | US | disclosed |
| US-20110281876-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2011-11-17 | — | — | US | disclosed |
| US-20110281876-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2041094-B1 | BIARYLCARBOXYARYLAMIDES AS VANILLOID-1 RECEPTOR MODULATORS | PHARMESTE SRL (IT) | 2011-06-29 | — | — | EP | disclosed |
| US-7964606-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20110009418-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110009418-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7799807-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799807-B2 | Therapeutic agents useful for treating pain | PURDUE PHARMA L.P. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20100081687-A1 | BIARYLCARBOXYARYLAMIDES AS VANILLOID-1 RECEPTOR MODULATORS | PHARMESTE S.R.L. (IT) | 2010-04-01 | — | — | US | disclosed |
| US-20100081687-A1 | BIARYLCARBOXYARYLAMIDES AS VANILLOID-1 RECEPTOR MODULATORS | PHARMESTE S.R.L. (IT) | 2010-04-01 | — | — | US | disclosed |
| EP-2017276-A1 | Phenyl-carboxamide compounds useful for treating pain | EURO-CELTIQUE S.A. (LU) | 2009-01-21 | — | — | EP | disclosed |
| WO-2008006480-A1 | BIARYLCARBOXYARYLAMIDES AS VANILLOID-1 RECEPTOR MODULATORS | PHARMESTE S.R.L. (IT) | 2008-01-17 | — | — | WO | disclosed |
| US-20060100245-A1 | Substituted biphenyl-4-carboxylic acid arylamide analogues | NEUROGEN CORPORATION (US) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009418-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | OPRL1, OPRK1, TRPV1 | TRPV1 3/4885 |
| US-20060100245-A1 | Substituted biphenyl-4-carboxylic acid arylamide analogues | HCAR2, AHR, HCAR3 | TRPV1 53/4885 |
| US-20110281876-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | OPRL1, OPRK1, TRPV1 | TRPV1 3/4885 |
| US-20100081687-A1 | BIARYLCARBOXYARYLAMIDES AS VANILLOID-1 RECEPTOR MODULATORS | TRPV1, TRPV3, TRPV2 | TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.